1 July 2014
Expansion of Bioanalytical Capabilities
Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the expansion of their bioanalytical capabilities within the BioHub site at Alderley Park in the UK to increase its offering to both existing customers and new customers in new markets.
The new instruments include a Waters Xevo® G2-S QTof high resolution accurate mass spectrometer (“QTof”), a LabLogic Beta-Ram® radiochemical detector and a Waters Atmospheric Pressure Gas Chromatography (APGC) system. This investment enables Cyprotex to improve its services to its existing pharmaceutical customers as well as unlock future potential in new markets such as the chemical and personal care markets.
Assessing the metabolites formed following drug exposure is a key part of the drug development process. The Waters Xevo® G2-S QTof mass spectrometer is one of the most advanced instruments for this purpose. By determining the accurate mass of the metabolites it enables more precise structural characterisation to be achieved. The new QTof can also be linked to a LabLogic Beta-Ram® radiochemical detector which complements this service allowing detection of radiochemicals and quantification of radiolabelled metabolites formed.
Although our current analytical equipment is suitable for the majority of molecules we test, it is not appropriate for certain classes of compounds and chemicals. As Cyprotex expands into the personal care and chemicals market, an ability to analyse more volatile compounds is required. The Company has therefore invested in gas chromatography which is a more appropriate platform for these types of molecules. Another key trend in the market is the preclinical development of large molecules. The QTof can analyse an extended range of molecular weights meaning the analysis of larger molecules is more achievable.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the expansion of the bioanalytical facility:
"Characterising the structural identity of drug metabolites is a critical part of the drug development process. By investing in the QTof and the radiochemical detector we can now provide a comprehensive service which is appropriate for late stage preclinical development projects required by the regulatory authorities.
“As we expand into new markets we are observing a shift in the requirements for bioanalysis, and we are adapting our business accordingly. We now have a wide range of solutions to cover our differing customers’ needs, allowing us to grow our existing business as well as attract customers from new markets.”
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotech’s to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.